ALETA 005
Alternative Names: ALETA-005Latest Information Update: 14 Aug 2023
At a glance
- Originator Aleta Biotherapeutics
- Class Antineoplastics; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Multiple myeloma
Most Recent Events
- 08 Aug 2023 Early research in Multiple myeloma in USA (Parenteral) (ALETA biotherapeutics pipeline, August 2023)